Hepatic Fibrosis: Emerging Therapies
Hepatic Fibrosis: Emerging Therapies
复制标题
DOI：
10.1159/000374098
复制
发表时间：
2015-01-01
影响因子：
2.3
通讯作者：
Friedman, Scott L.
中科院分区：
文献类型：
--
作者：
Friedman, Scott L.
对肝纤维化发病机制的认识已经取得了巨大的进展，这为肝纤维化的治疗创造了新的机会。纤维化可逆性的临床证据已经证实，肝脏具有吸收疤痕组织的能力，未来的治疗将部分基于这一见解。此外，肝星状细胞激活的范例为确定抗纤维化治疗的靶点提供了重要的模板。一旦生物标记物得到改进，临床试验的终点得到更好的定义，加快药物审批的机会比比皆是。总体而言，有令人鼓舞的证据表明，纤维化是慢性肝病的一种可治疗的后果，即使潜在的疾病尚未治愈，也可以进行治疗。(C)2015年S.Karger AG，巴塞尔
There has been tremendous progress made in understanding the pathogenesis of hepatic fibrosis, which has created new opportunities for the treatment of this condition. Clinical evidence of fibrosis reversibility has established that the liver has the capacity to resorb scar tissue, and future therapies will be based in part on this insight. Additionally, the paradigm of hepatic stellate cell activation provides an important template for defining targets of antifibrotic therapy. Opportunities abound to accelerate drug approvals once biomarkers are improved and endpoints of clinical trials are better defined. Overall, there is heartening evidence that fibrosis is a tractable consequence of chronic liver disease that will be amenable to therapy even when the underlying disease has not been cured. (C) 2015 S. Karger AG, Basel